<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4230">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682574</url>
  </required_header>
  <id_info>
    <org_study_id>IRBEC/BIH/09-2020</org_study_id>
    <nct_id>NCT04682574</nct_id>
  </id_info>
  <brief_title>Role of Mega Dose of Vitamin C in Critical COVID-19 Patients</brief_title>
  <official_title>Efficacy of Mega Dose Vitamin C in Critically Ill COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lahore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lahore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin C (ascorbic acid) is a water-soluble vitamin having anti-inflammatory,&#xD;
      immunomodulatory, anti-oxidative, antithrombotic and antiviral properties. Considering these&#xD;
      effects vitamin C should have beneficial impact in patients suffering from sepsis and acute&#xD;
      respiratory distress syndrome (ARDS). The current study is designed to assess the beneficial&#xD;
      effects of Vitamin C in COVID-19 infected patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">January 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial pressure of Oxygen in arterial blood to fraction of inspired Oxygen (P/F ratio)</measure>
    <time_frame>2 to 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>2 weeks</time_frame>
    <description>duration of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>vitamin C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dose would be 30 grams a day (10 grams TDS) for 2 days with standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Distill water in the same dose with same standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>mega dose is given to the selected critically ill patients</description>
    <arm_group_label>vitamin C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        critically ill patients admitted in ICU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        allergic to Vitamin C didnt given the consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Muhammad Mansoor Hafeez, MBBS</last_name>
    <phone>0923214231613</phone>
    <email>mansoor.hafeez@imbb.uol.edu.pk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Muhamma Asim Rana, MBBS, MRCP</last_name>
    <phone>0923435807006</phone>
    <email>drasimrana@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bahria Town International Hospital</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Asim Rana, MBBS, MRCP</last_name>
      <phone>0923435807006</phone>
      <email>drasimrana@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lahore</investigator_affiliation>
    <investigator_full_name>Dr Muhammad Mansoor Hafeez</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

